CureDuchenne celebrates Dyne Therapeutics’ public offering on the Nasdaq, under the ticker “DYN”. Today’s initial public offering (IPO) will elevate Dyne’s financial position and accelerate Dyne’s lead programs, which includes […]
Pratteln, Switzerland, September 14, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that Emory University scientists and partner ReveraGen Biopharma Inc. have published new data on the molecular mode of action of […]
Pratteln, Switzerland, September 11, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. has completed enrollment into the pivotal VISION-DMD study with vamorolone in patients with Duchenne muscular […]
• License gives Santhera worldwide rights to vamorolone, now also including the major marketsJapan and South Korea, and paves the way for partnering in additional indications• Agreements with Idorsia and […]
— FDA grants Priority Review Status and sets regulatory action date for February 25, 2021 —— FDA has indicated it does not currently plan to hold an advisory committee meeting […]
Get Involved with Project Euphonia Help future generations of people living with motor speech impairments. Automated speech recognition, which powers voice-activated technology such as the Google Assistant, are more common […]
NS Pharma Announcement of Viltepso: A New FDA-Approved Treatment for Patients With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 53 Skipping View this webinar to learn more about Viltepso from […]
CureDuchenne congratulates the incredible Dyne Therapeutics team, who recently announced closing $115M in equity financing to develop transformational therapies for patients with serious muscle diseases. We share this news in […]
CureDuchenne is thrilled to relay the news that NS Pharma has received FDA marketing authorization for Vitolarsen, an exon 53 skipping therapy. The entire Duchenne community is grateful for NS […]
